Status:
RECRUITING
Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research
Lead Sponsor:
Chinese PLA General Hospital
Collaborating Sponsors:
The First Hospital of Jilin University
Conditions:
Hepatocellular Carcinoma Stage III
Eligibility:
All Genders
18-80 years
Brief Summary
Hepatocellular carcinoma (HCC) is a highly heterogeneous malignant tumor with significant differences in invasion, proliferation ability and patient prognosis. Currently, there is a lack of non-invasi...
Eligibility Criteria
Inclusion
- According to the WHO classification, the pathological diagnosis is hepatocellular carcinoma.
- The initial treatment is curative-intent hepatectomy.
- There is no evidence of major vascular/hepatic portal invasion, extrahepatic/lymph node metastasis, or other malignant tumors.
- Age 18-80 years old.
Exclusion
- · Not meeting any one of the inclusion criteria or being unwilling/unable to follow-up.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06559761
Start Date
January 1 2023
End Date
December 31 2029
Last Update
August 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853